Rovi to Invest 40 Million in a New Compounding Plant in Fraga

Rovi expands its business in the southeast of the province of Huesca (Aragón). The pharmaceutical laboratory, Càrniques Celrà, and Grupo Empresarial Costa have created a joint venture under the name of Glicopepton Biotech, for the self-supply of heparins. The association will make possible the construction of a plant dedicated to the production of compounds of high biological value from the intestinal mucosa of pigs, with an investment of 40 million euros.

The plant will be located in the Fraga Logistics-Industrial Platform. The investment will be carried out over the next four years and the project foresees the creation of around thirty direct jobs, according to Rovi through a statement sent to the Spanish Securities and Exchange Commission (Comisión Nacional del Mercado de Valores, Cnmv).

Glicopepton Biotech combines Rovi’s experience as a company specializing in the research of low molecular weight heparins (Hbpm), with the experience of Càrniques Celrà and Grupo Empresarial Costa, two referents in the livestock and meat sector in Spain. Hbpm is an anticoagulant drug used to prevent and treat venous thromboembolic disease. It is a product of biological origin whose raw material is obtained from the intestinal mucosa of pigs.

Rovi, Càrniques Celrà, and Grupo Empresarial Costa have signed an investment and partners agreement which has given rise to the incorporation of the company Glicopepton Biotech, currently owned by Rovi, with 51% of the share capital, and by the other two partners, with 24.5% of the share capital each.

Discover the world’s most interesting financial news with the mobile app Born2Invest. The app provides its readers access to the latest news in global business, stock market, finance news, and also trending topics like bitcoin, cryptocurrency, and biotech.

Rovi controls 51% of the joint venture Glicopepton Biotech

Rovi has internal production capacity to transform crude heparin into sodium heparin and is planning to expand this capacity through the construction, already underway, of a new sodium heparin production line with the aim of being present in all the manufacturing stages of low molecular weight heparins.

Rovi is a specialized pharmaceutical company dedicated to the research, development, manufacturing under license, and commercialization of small molecules and biological specialties. The company, in a continuous process of international expansion, has subsidiaries in Portugal, Germany, United Kingdom, Italy, France, and Poland and has a diversified portfolio of more than forty marketed products, in which its reference product, Bemiparin, which is already marketed in 89 countries around the world, stands out.

Likewise, in 2017 the Spanish pharmaceutical company began marketing its internally developed biosimilar enoxaparin in Europe, which is already marketed in 38 countries.

__

(Featured image by alfcermed via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.